A Study of NX-1607 in Adults With Advanced Malignancies

ClinicalTrials.gov ID: NCT05107674

Public ClinicalTrials.gov record NCT05107674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Study identification

NCT ID: NCT05107674
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Enrollment: 345 participants

Conditions and interventions

Conditions

Interventions

NX-1607 Drug
Paclitaxel Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 28, 2021
Primary completion: Aug 30, 2026
Completion: Feb 27, 2028
Last update posted: Sep 8, 2025

2021 – 2028

United States locations

U.S. sites: 10
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Completed
University of Southern California	Los Angeles	California	90007	Recruiting
University of California, San Francisco	San Francisco	California	94158	Recruiting
University of Colorado School of Medicine	Aurora	Colorado	80045	Recruiting
University of Chicago	Chicago	Illinois	60637	Recruiting
University of North Carolina	Chapel Hill	North Carolina	27599	Recruiting
University of Oklahoma	Oklahoma City	Oklahoma	73104	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Virginia	Charlottesville	Virginia	22908	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05107674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 8, 2025 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05107674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →